Log In
BCIQ
Print this Print this
 

RXDX-106 (formerly CEP-40783)

  Manage Alerts
Collapse Summary General Information
Company Ignyta Inc.
DescriptionSelective, pseudo-irreversible inhibitor of AXL receptor tyrosine kinase (AXL; UFO) and c-Met receptor tyrosine kinase (c-MET; MET; c-Met proto-oncogene)
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene) ; AXL receptor tyrosine kinase (AXL) (UFO)
Mechanism of Actionc-Met receptor tyrosine kinase inhibitor; AXL receptor tyrosine kinase (AXL) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$11.3M

0

0


 Deals Details
Get a free BioCentury trial today